Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 4 25 M IN DEXTROSE 10 IN PLASTIC CONTAINER versus NEOPHAM 6 4.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 4 25 M IN DEXTROSE 10 IN PLASTIC CONTAINER versus NEOPHAM 6 4.
AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER vs NEOPHAM 6.4%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn II 4.25% M in Dextrose 10% is a combination of amino acids and dextrose used for parenteral nutrition. Amino acids provide substrates for protein synthesis, while dextrose provides a source of calories. The amino acids undergo transamination, deamination, and incorporation into body proteins. Dextrose is metabolized via glycolysis, the Krebs cycle, and oxidative phosphorylation to produce ATP.
NEOPHAM 6.4% is a sterile, nonpyrogenic, hypertonic solution of amino acids and glycerin used for parenteral nutrition. It provides essential and non-essential amino acids to support protein synthesis and energy metabolism, with glycerin serving as a non-glucose caloric source to reduce hyperglycemia. The amino acids are utilized for tissue repair and growth, while glycerin is metabolized via gluconeogenesis and glycolysis.
Intravenous infusion via central line. Adult dose: 500-2000 mL/day (equivalent to 21.25-85 g amino acids and 50-200 g dextrose) based on caloric and nitrogen requirements. Rate not to exceed 100 mL/hour initially, adjusted to maintain blood glucose <200 mg/dL.
Intravenous infusion of 6.4% amino acid solution at 0.8-1.5 g/kg/day (equivalent to 12.5-23.4 mL/kg/day) for protein replenishment; typical adult dose 500-1000 mL/day infused at 1-2 mL/min.
None Documented
None Documented
Amino acids: variable; individual amino acid half-lives range from minutes to hours; dextrose: 1-2 hours; clinical context: continuous infusion required to maintain stable plasma levels.
Not applicable as a single entity; amino acids have varying half-lives (minutes to hours depending on individual amino acid and metabolic state). Clinical context: continuous infusion used for parenteral nutrition; no terminal elimination half-life defined for the mixture.
Renal: amino acids are metabolized and nitrogen is excreted primarily as urea (80-90%) and ammonia (minor); dextrose is fully metabolized to CO2 and water; negligible biliary/fecal elimination.
Renal elimination of absorbed amino acids and metabolites; minimal biliary/fecal excretion. >90% of infused amino acids are reincorporated into body protein or metabolized; excess nitrogen excreted as urea in urine.
Category C
Category C
Amino Acid Solution
Amino Acid Solution